IFP Advisors’s First Tracks Biotherapeutics TRAX Stock Holding History

IFP Advisors’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1	Closed	-$20	–	5444
2026 Q2	$20	Buy	+1	New	+$19	﹤0.01%	5075

Other funds holding TRAX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

IFP Advisors's TRAX Position: Q3 2026 in Review

IFP Advisors sold out of First Tracks Biotherapeutics (TRAX) in Q3 2026, closing a stake of 1 share — an estimated $20 sold.

IFP Advisors first reported a position in TRAX in Q2 2026 and held it in 1 quarter. The position peaked at $20 in Q2 2026. 56 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

IFP Advisors reported no remaining First Tracks Biotherapeutics position as of Q3 2026 after selling out during the quarter.
IFP Advisors sold 1 First Tracks Biotherapeutics share in Q3 2026, an estimated $20.
IFP Advisors first reported a position in First Tracks Biotherapeutics in Q2 2026 and held it in 1 quarter.
IFP Advisors's First Tracks Biotherapeutics position peaked at $20 in Q2 2026.
56 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.